Increased leptin expression selectively in the hypothalamus suppresses inflammatory markers CRP and IL-6 in leptin-deficient diabetic obese mice.
Low-grade systemic inflammation, as indicated by increased circulating levels of inflammatory markers CRP and IL-6, is linked to increased risks for cardiovascular diseases (CVD) and diabetes mellitus in obese subjects. Whereas hyperleptinemia in obesity are associated with increased CRP and IL-6 release, the hypothalamic versus peripheral site of leptin action has not been ascertained. The effects of increased leptin supply selectively in the hypothalamus by gene therapy on pro-inflammatory CRP and IL-6 levels and on markers of diabetes in the circulation of ob/ob mice displaying either age-related or dietary obesity were assessed. A recombinant adeno-associated viral vector encoding either green-fluorescent protein (control) or leptin gene was injected intracerebroventricularly. Five weeks later, one-half of each of the vector groups was switched to high-fat diet consumption and the other half continued to consume regular low-fat chow diet. Body weight and visceral white adipose tissue were drastically reduced and hyperinsulinemia and hyperglycemia were abrogated by leptin gene therapy, independent of the dietary fat content. The elevated plasma CRP and IL-6 levels seen in obese ob/ob mice receiving the control vector, regardless of the fat content of the diet, were markedly suppressed by increased hypothalamic leptin in both groups. The results show for the first time that leptin deficiency elevates and reinstatement of leptin selectively in the hypothalamus suppresses the release of pro-inflammatory biomarkers, a response likely to alleviate CVD associated with obesity.
Dube
Michael G
MG
Department of Physiology and Functional Genomics, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL 32610-0244, USA.
Torto
Rita
R
Kalra
Satya P
SP
D000818:Animals; D015415:Biomarkers / Q000097:blood; D001835:Body Weight; D002097:C-Reactive Protein / Q000032:analysis*; D048909:Diabetes Complications / Q000276:immunology*; D005822:Genetic Vectors / Q000008:administration & dosage; D007031:Hypothalamus / Q000378:metabolism*; D015850:Interleukin-6 / Q000097:blood*; D020738:Leptin / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008820:Mice, Obese; D008822:Mice, Transgenic; D009765:Obesity / Q000150:complications*
D015415:Biomarkers; D015850:Interleukin-6; D020738:Leptin; D002097:C-Reactive Protein